Hypocellular myelodysplastic syndrome with myelofibrosis in acute myeloid leukemia transformation: A case report

Song,Kui; Xu,Xiaojun; Li,Min

doi:10.3892/ol.2015.3247

Hypocellular myelodysplastic syndrome with myelofibrosis in acute myeloid leukemia transformation: A case report

Authors:
- Kui Song
- Xiaojun Xu
- Min Li
View Affiliations

Affiliations: Department of Hematology, The Affiliated Zhongshan Hospital, Sun Yat‑Sen University, Zhongshan, Guangdong 528403, P.R. China, Department of Pharmacy, The First Affiliated Hospital of Jishou University, Jishou, Hunan 416000, P.R. China
Published online on: May 20, 2015 https://doi.org/10.3892/ol.2015.3247
Pages: 422-424

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Primary myelodysplastic syndrome (MDS) with myelofibrosis is a rare hematological disorder that should be classified as a distinct subgroup of MDS. Treatment of MDS with myelofibrosis remains problematic and the prognosis is poor in these patients, particularly following transformation into acute myeloid leukemia (AML). The current study presents the case of a 28‑year‑old male diagnosed with MDS associated with myelofibrosis, together with hypocellular bone marrow features. Following induction chemotherapy consisting of mitoxantrone and cytarabine, the patient achieved complete remission, but developed severe myelofibrosis. The patient relapsed and the disease transformed into AML 12 months later. However, the extent of the myelofibrosis was markedly alleviated upon administration of a FLAG regimen that consisted of fludarabine, cytarabine and granulocyte colony‑stimulating factor during the AML transformation. After one course of the FLAG regimen, the patient achieved a second complete remission. As there was no suitable donor for hematopoietic stem cell transplantation (HSCT), the patient relapsed and succumbed shortly after. In conclusion, MDS with fibrosis is an aggressive disease, but the degree of myelofibrosis may not be associated with the progression of hypocellular MDS, and allogeneic HSCT remains a potentially curative option for affected patients.

View Figures

View References

1	Fu B, Ok CY, Goswami M, Xei W, Jaso JM, Muzzafar T, Bueso-Ramos C, Verstovsek S, Garcia-Manero G, Medeiros LJ, et al: The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes. Ann Hematol. 92:1335–1343. 2013. View Article : Google Scholar : PubMed/NCBI
2	Akyay A, Olcay L, Kuzu I, Bozdoğan N, Ünal-İnce E, İleri T, Tükün A and Yürür-Kutlay N: A child with myelodysplastic syndrome with hypocellular fibrosis. J Pediatr Hematol Oncol. 32:617–620. 2010. View Article : Google Scholar : PubMed/NCBI
3	Orazi A and Czader MB: Myelodysplastic syndromes. Am J Clin Pathol. 132:290–305. 2009. View Article : Google Scholar : PubMed/NCBI
4	Savona MR: Are we altering the natural history of primary myelofibrosis. Leuk Res. 38:1004–1112. 2014. View Article : Google Scholar : PubMed/NCBI
5	Lekovic D, Gotic M, Perunicic-Jovanovic M, Vidovic A, Bogdanovic A, Jankovic G, Cokic V and Milic N: Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis. Med Oncol. 31:8692014. View Article : Google Scholar : PubMed/NCBI
6	Quintás-Cardama A, Kantarjian H, Pierce S, Pierce S, Cortes J and Verstovsek S: Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 13:315–318. 2013. View Article : Google Scholar : PubMed/NCBI
7	Saunthararajah Y: Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes. Hematology Am Soc Hematol Educ Program. 2013:511–521. 2013. View Article : Google Scholar : PubMed/NCBI
8	Ossenkoppele GJ, Graveland WJ, Sonneveld P, Daenen SM, Biesma DH, Verdonck LF, Schaafsma MR, Westveer PH, Peters GJ, Noordhuis P, et al: The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood. 103:2908–2913. 2004. View Article : Google Scholar : PubMed/NCBI
9	Virchis A, Koh M, Rankin P, Mehta A, Potter M, Hoffbrand AV and Prentice HG: Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes. Br J Haematol. 124:26–32. 2004. View Article : Google Scholar : PubMed/NCBI
10	Varma N and Varma S: Proliferative indices, cytogenetics, immunophenotye and other prognostic parameters in myelodysplastic syndromes. Indian J Pathol Microbiol. 51:97–101. 2008. View Article : Google Scholar : PubMed/NCBI
11	Marisavljević D, Rolović Z, Cemerikić V, Bosković D and Colović M: Myelofibrosis in primary myelodysplastic syndromes: clinical and biological significance. Med Oncol. 21:325–331. 2004. View Article : Google Scholar : PubMed/NCBI
12	Nokes TJ, Johnson S, Harvey D and Goldstone AH: FLAG is a useful regimen for poor prognosis adult myeloid leukaemias and myelodysplastic syndromes. Leuk Lymphoma. 27:93–101. 1997.PubMed/NCBI
13	Huang WH, Li MS, Chu SC, Wang TF, Kao RH and Wu YF: Thalidomide treatment in a myelofibrosis patient with leukemia transformation. Int J Hematol. 99:188–192. 2014. View Article : Google Scholar : PubMed/NCBI
14	Della Porta MG and Malcovati L: Myelodysplastic syndromes with bone marrow fibrosis. Haematologica. 96:180–183. 2011. View Article : Google Scholar : PubMed/NCBI
15	Algarni AA, Akhtari M and Fu K: Myelodysplastic syndrome with myelofibrosis transformed to a precursor B-cell acute lymphoblastic leukemia: A case report with review of the literature. Case Rep Hematol. 2012:2075372012.PubMed/NCBI